supplements€¦ · or otherwise, or from any use or operation of any methods, products,...

SUPPLEMENTS

Official Journal of the European Atherosclerosis SocietyAffiliated with the International Atherosclerosis Society and

the Society of Atherosclerosis Imaging and Prevention

Volume 7/3 (2006)

Amsterdam • Boston • Jena • London • New York • Oxford • Paris • Philadelphia • San Diego • St. Louis

© 2006 Elsevier Ireland Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Ireland Ltd., and the following termsand conditions apply to their use:

PhotocopyingSingle photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher andpayment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotionalpurposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies fornon-profit educational classroom use.

Permissions may be sought directly from Elsevier’s Rights Department in Oxford, UK: phone: (�44) 1865 843830; fax: (�44) 1865 853333;e-mail [email protected]. Requests may also be completed on-line via the Elsevier homepage (http://www.elsevier.com/locate/permissions).

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers,MA 01923, USA; phone: (�1) (978) 7508400; fax: (�1) (978) 7504744, and in the UK through the Copyright Licensing Agency RapidClearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (�44) 20 7631 5555; fax: (�44) 20 7631 5500.Other countries may have a local reprographic rights agency for payments.

Derivative WorksSubscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions.Permission of the Publisher is required for resale or distribution outside the institution.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or UsagePermission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of anarticle.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by anymeans, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier Rights Department, at the fax and e-mail addresses noted above.

NoticeNo responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligenceor otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapidadvances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute aguarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).



EDITORS

E.J. Schaefer (Boston, MA) – J. Shepherd (Glasgow)

ASSOCIATE EDITORS

D. Freeman (Glasgow) – K. Kajinami (Kanazawa)

HONORARY EDITORS

D. Kritchevsky (Philadelphia, PA) – D. Seidel (Munich) – G. Schonfeld (St. Louis, MO)

REVIEWS EDITOR

A. Gaw (Glasgow)

EDITORIAL BOARD

L. Badimon (Barcelona)P.J. Barter (Sydney)D.M. Black (Princeton, NJ)A. Blann (Birmingham)M.E. Brousseau (Cambridge,

MA)R. Bruckdorfer (London)S. Calandra (Modena)G. Camejo (Mölndal)G.R. Campbell (Queensland)A. Catapano (Milan)M.J. Chapman (Paris)J.S. Cohn (Sydney)P. Couture (Quebec City)G. Dallinga-Thie (Utrecht)J. Dallongeville (Lille)P.N. Durrington (Manchester)Z.A. Fayad (New York, NY)R. Forough (College Station,

TX)B. Griffin (Guildford)R.A. Hegele (London, Ont.)S. Horiuchi (Kumamoto)B.I. Hudson (New York, NY)

S. Humphries (London)E. Hurt-Camejo (Göteborg)D.R. Illingworth (Portland, OR)E.D. Janus (Melbourne)J.Y. Jeremy (Bristol)W. Jessup (Sydney)I. Jialal (Sacramento, CA)R.H. Karas (Boston, MA)F. Karpe (Oxford)M.B. Katan (Wageningen)T. Kita (Kyoto)T. Kodama (Tokyo)G.M. Kostner (Graz)L. Kritharides (Sydney)E. Leitersdorf (Jerusalem)A.P. Levy (Haifa)A.H. Lichtenstein (Boston, MA)M.I. Mackness (Manchester)S. Marcovina (Seattle, WA)L. Masana (Reus)Y. Matsuzawa (Osaka)Y. Momiyama (Saitama)E.H. Moriguchi (Porto Alegre)P.J. Nestel (Melbourne)

J. Pears (Macclesfield)P. Raggi (New Orleans, LA)Z. Reiner (Zagreb)A. Remaley (Bethesda, MD)R.A. Riemersma (Edinburgh)R.S. Rosenson (Chicago, IL)P. Rubba (Naples)L.L. Rudel (Winston-Salem, NC)Y. Saito (Chiba)N. Sattar (Glasgow)G. Schmitz (Regensburg)A.D. Sniderman (Montreal)U.P. Steinbrecher (Vancouver,

BC)K.E. Suckling (Stevenage)W.H.F. Sutherland (Dunedin) E.S. Tai (Singapore)C.-E. Tan (Singapore)A.J. Taylor (Washington, DC)M.J. Tikkanen (Helsinki)A. Van Tol (Rotterdam)A. von Eckardstein (Zürich)G.F. Watts (Perth)S. Yamashita (Osaka)

EDITORIAL ASSISTANTS

E. Harasti (Boston, MA) – J. McIntosh (Glasgow)



AIMS AND SCOPE

Aims and Scope. Atherosclerosis brings together from all sources papers concerned with research and investigation onatherosclerosis, its complications and related diseases, including: lipoprotein metabolism, arterial and vascular biology anddisease, thrombosis, inflammation, disorders of lipid transport, diabetes and hypertension as related to atherosclerosis, andcardiovascular risk factors. The editors are also interested in clinical papers dealing with case studies of specific or generalinterest, new or unusual lipid syndromes, and the genetic basis and familial incidence of atherosclerosis and related diseases.High quality reports of controlled clinical trials of drugs or diets will be considered provided the paper deals with the mechanismof action of the drug or diet.

Society affiliations. Atherosclerosis is the official journal of the European Atherosclerosis Society (EAS). EAS membersreceive Atherosclerosis as part of their membership. For more information on membership please contact: Prof. SebastianoCalandra, Department of Biomedical Sciences, University of Modena & Reggio Emilia, Via Campi 287, I-41100 Modena,Italy. Tel.: (+39) 059 2055 423; Fax: (+39) 059 2055 426. E-mail: [email protected]; EAS website: www.eas-society.org

Atherosclerosis is also affiliated with the International Atherosclerosis Society (IAS). A reduced personal subscription rate isavailable to all members of the IAS. For more information on membership please contact the IAS offices: Administration,Education, and Scientific Affairs, Emanuela Folco, Ph.D., Executive Director, International Atherosclerosis Society, ViaAppiani 7, 20121 Milan, Italy, E-mail: [email protected]; IAS website: www.athero.org

Atherosclerosis is also affiliated to the Society of Atherosclerosis Imaging and Prevention (SAIP). All members receive thejournal as part of their membership. The SAIP president and representative to the journal is: Zahi Fayad, PhD (New York, NY).For more information on membership, please contact William D. Nelligan, Executive Director, 26804 Ridge Rd., Damascus,MD 20872 (USA). Tel.: (+1) 301 253 4155; Fax: (+1) 301 414 7535; E-mail: [email protected]; SAIP website: www.sai-p.org

International Atherosclerosis Society: Subscription rates for members are available on request from the Publisher.

Publication information: Atherosclerosis Supplements (1567-5688) publishes supplements to Atherosclerosis (0021-9150).For 2006, volumes 184–189 are scheduled for publication. Subscription prices are available upon request from the Publisher orfrom the Regional Sales Office nearest you or from this journal’s website (http://www.elsevier.com/locate/atherosclerosis).Further information is available on this journal and other Elsevier products through Elsevier’s website: (http://www.elsevier.com). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sentby standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims formissing issues should be made within six months of the date of dispatch.



ContentsVol. 7 No. 3 (June 2006)

Cited in: Biological Abstracts – Chemical Abstracts –Current Contents/Life Sciences – Current Contents/Clinical Medicine – Elsevier BIOBASE/Current Awareness in Biological

Sciences – EMBASE/Excerpta Medica Abstract Service – Index Internacional de Cardiologia – Medline/Index Medicus –Informedicus – PASCAL M – Sociedad Iberoamericana de Información Cientifica (SIIC)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

Sunday June 18, 2006

Joint ISA 2006–National Lipid Association (NLA) Symposium 1Su-S1 Report of the NLA Task Force on statin safety 1Su-S2 Etiology of the metabolic syndrome? 2

Symposium 5Su-S3 Genomic research in cardiovascular medicine and the support of technology 5

Monday June 19, 2006

Plenary Session 7Mo-PL1 Vascular biology 7

Master Lecture 9Mo-ML1 Dyslipidemia in renal impairment – from pathophysiology to evidence 9Mo-ML2 Novel imaging in atherosclerotic vascular disease: glimpse into plaque characterization 9Mo-ML3 Edible plants and optimized nutrition 10

Workshop 11Mo-W1 Pharmacology of arterial disease: HDL-targeted therapies (1st part) 11Mo-W2 Diabetes and atherosclerosis 13Mo-W3 Lipases 15Mo-W4 Stroke 17Mo-W5 The European Network for inherited dyslipidemia 19Mo-W6 Atherosclerosis: basic science (1st part) 20Mo-W7 Biomarkers for risk determination: novel risk factors 22Mo-W8 Metabolic syndrome (1st part) 24Mo-W9 Cellular lipid trafficking 26Mo-W10 Thrombosis (1st part) 28Mo-W11 Post-prandial lipemia 30Mo-W12 Progenitor cells and angiogenesis 32Mo-W13 Genetics (1st part) 34Mo-W14 Biomarkers for risk determination: new laboratory approaches 36Mo-W15 Lipid and lipoprotein metabolism 38

The Table of Contents, Instructions to Authors and other information on Atherosclerosis, can beaccessed on the World Wide Web at the following URL address:

http://www.elsevier.com/locate/atherosclerosis

vi Contents

Sponsored Symposium 40Mo-S4 CB1 blockade: new approach for the management of atherogenic dyslipidaemia and multiple cardiometabolic

risk factors in abdominally obese patients 40Mo-S6 New technologies: prediction of coronary event risk 41Mo-S7 Helping to set a new standard in cholesterol management: treating 2 sources of cholesterol 43

Poster Session 46P1 Epidemiology of cardiovascular disease 46P2 Pathophysiology of thrombosis 83P3 Gene therapy and stem cells 94P4 Clinical aspects of cardiovascular disease 97P5 Clinical practice in cardiovascular disease 111P6 Genetics of cardiovascular disease 128

Tuesday, June 20, 2006

Plenary Session 149Tu-PL2 Lipoproteins and thrombosis 149

Master Lecture 151Tu-ML4 Endothelial dysfunction and atherosclerosis: mechanisms and therapeutical intervention 151Tu-ML5 Cardiovascular consequences of cyclooxygenase inhibition; pharmacological targets beyond COX-2 151

Workshop 152Tu-W16 HDL functions 152Tu-W17 Metabolic syndrome (2nd part) 154Tu-W18 Unstable plaque 156Tu-W19 Thrombosis (2nd part) 158Tu-W20 Clinical trials (1st part) 160Tu-W21 Novel aspects of clinical practice: HIV infection and physical activity 162Tu-W22 Adipose tissue 164Tu-W23 HDL cholesterol and reverse transport 166Tu-W24 Inflammation (1st part) 167Tu-W25 Lifestyle and clinical practice 169Tu-W26 Platelets 171Tu-W27 Clinical trials (2nd part) 174Tu-W28 Nutritional approaches: the global picture 175Tu-W29 Pharmacoeconomy 178

Sponsored Symposium 180Tu-S8 CETP inhibitors and their effects on cardiovascular risk factors 180Tu-S9 Omega-3 fatty acids in cardiovascular disease 180Tu-S10 New treatment paradigms: intensive cholesterol lowering therapy 182Tu-S11 Atherosclerosis: from lipids to coronary heart disease 183

Poster Session 185P7 Basic science (1st part) 185P8 Basic science (2nd part) 249P9 Diagnostic technologies for cardiovascular diseases 258P10 Biomarkers for cardiovascular disease 270

Wednesday, June 21, 2006

Plenary Session 301We-PL3 Novel approaches to treatment 301

Master Lecture 303We-ML6 Lifestyle modulation of inflammatory processes 303We-ML7 The metabolic syndrome in an elderly Italian cohort: the ILSA study 303We-ML8 POSCH trial and the initial proof of the cholesterol hypothesis: implications for today 304


Contents vii

Workshop 305We-W30 Familial hyper- and hypolipidemias 305We-W31 Diagnostic technologies for arterial diseases (1st part) 307We-W32 Inflammation (2nd part) 309We-W33 Obesity and weight reduction (1st part) 310We-W34 Diagnostic technologies for arterial diseases: arterial physiology 312We-W35 Genetics (2nd part) 314We-W36 Intervention at the population level 316We-W37 Animal models (1st part) 318We-W38 Pharmacology of arterial disease: HDL-targeted therapies (2nd part) 320We-W39 Diagnostic technologies for arterial diseases (2nd part) 322We-W40 Antithrombotic therapy 324We-W41 Immune system 326We-W42 Obesity and weight reduction (2nd part) 328We-W43 Lipoprotein receptors 330We-W44 Genetics (3rd part) 332We-W45 Epidemiology of cardiovascular disease: prevention 334

Sponsored Symposium 337We-S12 Phytosterol-based functional foods: new tools in cardiovascular prevention 337We-S13 Inhibition of squalene synthase 338

Joint ISA 2006–International Chair on Cardiometabolic Risk Symposium 340We-S14 International chair on cardiometabolic risk 340

Sponsored Symposium 342We-S15 Key questions in the management of patients with type 2 diabetes: new findings from the FIELD trial 342We-S16 Dietary approaches for atherosclerosis prevention: vegetable protein 343

Poster Session 346P11 Optimal atherosclerosis management (1st part) 346P12 Optimal atherosclerosis management (2nd part) 407P13 Metabolic syndrome 415P14 Nutritional approaches 430

Thursday, June 22, 2006

Plenary Session 457Th-PL4 From clinical trials to practice 457

Workshop 459Th-W46 Oxidation 459Th-W47 Cholesterol risk factors and management: a success or a failure? 461Th-W48 Animal models (2nd part) 462Th-W49 Pharmacology of arterial disease: novel therapeutic approaches (1st part) 464Th-W50 Guidelines and global risk (1st part) 466Th-W51 Hypertension 468Th-W52 Ageing 470Th-W53 Unsaturated fatty acids 472Th-W54 Lipoprotein particle 474Th-W55 Vegetable proteins 476Th-W56 Biomarkers for risk determination 478Th-W57 Pharmacology of arterial disease: novel therapeutic approaches (2nd part) 481Th-W58 Guidelines and global risk (2nd part) 483Th-W59 Menopause: new approaches to intervention 485Th-W60 Atherosclerosis: basic science (2nd part) 487Th-W61 Animal models (3rd part) 489

Celebrating Session 491Th-S17 50th Anniversary of the ultracentrifugal separation of lipoproteins in clinical science 491


viii Contents

Poster Session 492P15 Pathophysiology of lipids and lipoproteins 492P16 Pharmacological control of lipids and lipoproteins 547P17 Novel technologies for risk determination 585

Topic Index 593

Author Index 611

CorrigendumCorrigendum to Abstract W12-P-063 “Obesity: Fatty acids, omega-6/omega-3 ratio and inflammatory markers”

[ATHSUP Volume 6, issue 1 (April 2005) page 77]R. Santos, A. Soares, B. Oliveira, J. Freitas, M. Macedo, I. Rebelo (Portugal) 663

ErratumErratum to “A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis”

[ATHSUP Volume 6, issue 4 (December 2005) 41–46]R. Morishita (Japan) 664


European Atherosclerosis Society

Executive Committee

EAS OfficeIrene Jack: Executive OfficerAltonagatan 7Malmö, SE 211 38, SwedenTel.: �46 40 240750Fax: �46 40 240751E-mail: [email protected]

President:Prof. Marja-Riitta TaskinenHelsinki University HospitalBiomedicumHaartmaninkatu 8, P.O. Box 70000029 Helsinki, FinlandTel.: �358-9-4717 1990Fax: �358-9-4717 1992E-mail: [email protected]

Secretary:Prof. Lale TokgozogluDept. of CardiologyHacettepe UniversityAnkara – TurkeyTel.: �90-312-467 0405Fax: �90-312-466 1906E-mail: [email protected]

Treasurer:Prof. Stephen HumphriesCardiovascular GeneticsBritish Heart Foundation LaboratoriesRoyal Free and University CollegeMedical SchoolRayne BuildingUniversity StreetLondon WC1E 6JJ, UKTel.: �44-(0)20-7679 6962Fax: �44-(0)20-7679 6212E-mail: [email protected]

Executive Officer:

Irene JackEuropean Atherosclerosis Society, Altonagatan 7, SE-211 38 Malmö/SwedenTel.: �46-40-240750; Fax: �46-40-240751; E-mail: [email protected]

Prof. Anton Stalenhoef463 Department of Medicine, Radboud University Nijmegen Medical Centre, P.O. Box 9101, NL-6500 Nijmegen, The NetherlandsTel.: �31 (0)24 361 8819; Fax: �31 (0)24 354 1734; E-mail: [email protected]

Prof. Jan BorenInstitute of Medicine, Wallenberg Laboratory, Sahlgrenska Univ. Hospital, SE-413 45, SwedenTel.: �46-31-342 29 49; Fax: �46-31-823762; E-mail: [email protected]

Assoc. Prof. Antonis ZampelasDept. of Nutrition and Dietetics, Harokopio University, 70, El. Venizelou, GR-17671 Athens, GreeceTel.: �30 (210) 9549 153; Fax: �30 (210) 9549 141; E-mail: [email protected]

Prof. Andrea Mezzetti, MDDept. of Medicine & Aging, CRC- Edificio ‘C.E.S.I.’, University “G. d’Annunzio, Chieti-Pescara, Via Colle dell’Ara, 66013 Chieti, ItalyTel.: �39-0871-541336; Fax: �39-0871-541337; E-mail [email protected]

Atherosclerosis is the disease of arteries that is the usual cause of heart attacks and stroke. The European Atherosclerosis Society, founded in 1964, is devoted to advancing knowledge of the causes, natural history, treatment and prevention of the disease, as stipulated by the Society’s constitution. Currently composed of over 450 senior and junior researchers in basic as well as clinical science, membership is open to scientists working in Europe and in neighbouring countries.

One major activity of the European Atherosclerosis Society is the organization of a large annual congress as well as several smaller scientific workshops. Another is the development of guidelines for the treatment and especially the prevention of atherosclerotic disease based on sound scientific evidence.

Major decisions are made by all Society Members by ballot or when assembled at the Annual Business Meeting. An Executive Committee, to which members are elected for a term of three years, takes care of the Society’s daily activities. The Society collaborates with other societies in the field of cardiovascular research. Society activities are supported by membership fees as well as by public and private sponsors.

Our Homepage on the Internet:www.eas-society.org


Forthcoming Scientific Congresses of the EAS/IAS

XIV International Symposium on AtherosclerosisRome, Italy, June 18–22, 2006Website: www.isa2006.org

76th EAS CongressHelsinki, Finland, June 10–13, 2007The Official EAS Helsinki SecretariatEAS2007 c/o Kenes International17 Rue du CendrierP.O. Box 1726CH-1211 Geneva 1SwitzerlandTel: +41 22 9080488Fax: +41 22 7322850Website: www.eas2007.fi


Information for Membership Application

Below are the articles from the EAS Constitution concerning Membership:

ARTICLE 3 – MEMBERSHIP

(a) Persons residing in Europe or neighbouring countries engaged in, or who direct research for, the purpose set out in Article 2 shall be eligible for membership of the Society.

(b) Membership of the Society shall be subdivided into Ordinary, Honorary, Corresponding and Corporate members.(c) Ordinary members shall be entitled to full privileges of the Society, namely, to hold office, to vote, to take part in the business of the Society,

to participate in its social and its scientific activities.Ordinary members shall pay the full annual subscription plus an appropriate annual subscription to the International Atherosclerosis Society, with which the Society is affiliated.

ARTICLE 5 – ELECTION PROCEDURES

(a) Election of Ordinary membersCandidates for election to Ordinary membership of the Society shall be proposed, seconded and balloted upon as follows:

i. Nomination forms for membership shall be distributed by the Secretary of the Society and shall be available to participants at all EAS meetings.

ii. Candidates must be proposed by two Members of the Society. The proposer must be fully conversant with the work of the nominee.iii. All membership applications shall be sent with the signed support of two Society members to the Secretary of the Society. The Executive

Committee shall scrutinise the nomination papers and will send the list of candidates to the membership of the Society for approval. If noobjections, made in writing, are received by the Secretary within 4 weeks, the list will be considered approved.

The membership fee for ordinary members is 88 Euro per year. This fee includes subscription of ATHEROSCLEROSIS (official journal of the EAS).

Further information:

To apply for membership the Application Form must be filled out and sent to the Secretary of the Society or the EAS office. Make sure that name and address are clearly written. The application must be sent to the EAS secretariat by fax or e-mail. You can get further information as well as additional application sheets from the EAS website – www.eas-society.org

European Atherosclerosis Society – Membership Application Form

Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Phone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year of Birth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

E-mail address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Research Speciality

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Brief Details of Academic Career and Present Position

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Date and Signature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Please return to the EAS Office.Irene Jack, Altonagatan 7, Malmö, SE 211 38, Sweden, Tel.: �46 40 240750; Fax: �46 40 240751; E-mail: [email protected]

International Atherosclerosis Societywww.athero.org

Officers and Board

PresidentWebsite Editor-in-ChiefScott M. Grundy, M.D., Ph.D.Director, Center for Human NutritionThe University of Texas SouthwesternMedical Center at Dallas – Room Y3-2065323 Harry Hines BoulevardDALLAS TX 75390-9052 (USA)Tel.: +1-214-648-2890Fax: +1-214-648-4837E-mail: [email protected]

Past PresidentHeiner Greten, M.D.ChairmanHanseatisches Herzzentrum HamburgLohmühlenstraße 5D- 20099 HAMBURG (GERMANY)E-mail: [email protected]

President-ElectJean-Charles Fruchart, Ph.D.Head, Department of AtherosclerosisInserm UR545, Institut Pasteur de LilleUniversity of Lille II1, rue du Professeur CalmetteF-59019 LILLE (FRANCE)E-mail: [email protected]

SecretaryMarja-Riitta Taskinen, M.D., Ph.D.Professor of MedicineHelsinki University HospitalBiomedicumUniversity of HelsinkiHaartmaninkatu 8, P.O. Box 700FIN-00029 HELSINKI (FINLAND)E-mail: [email protected]

TreasurerWalter F. Riesen, M.D.DirektorInstitut für Chemie und HämatologieKantonsspitalCH-9007 ST. GALLEN(SWITZERLAND)E-mail: [email protected]

Members-at-LargeEmilio Moriguchi, M.D., Ph.D.Philip Barter, M.D., Ph.D.M. John Chapman, Ph.D.

Regional Federation ChairsJean Davignon, M.D.S. Lale Tokgözoglu, M.D.Yuji Matsuzawa, M.D.

Senior Advisers to the BoardAntonio M. Gotto, Jr., M.D., D.Phil.Rodolfo Paoletti, M.D., Ph.D.

President XIV ISACesare R. Sirtori, M.D., Ph.D.

The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science,research and teaching in the field of atherosclerosis. The IAS endeavors to achieve these objectives by promoting the exchange of existingknowledge; encouraging new research ventures and interdisciplinary approaches; establishing visiting fellowships for investigators; fosteringthe dissemination of knowledge by organizing international symposia, interim meetings, and courses, and through association with scientificjournals; developing international guidelines, endorsed by the member societies: the most recent ones “Harmonized Clinical Guidelines onPrevention of Atherosclerotic Vascular Disease” were published in March 2003 and a pocket guide was also produced and distributed.

Membership is open to active researchers who join one of the 56 IAS national constituent societies or who join as individual membersfrom countries that do not have a national affiliated society; and to corporate organizations facilitating the objectives of the IAS. For alisting of member societies and additional information on structure, membership, congress activities, slide library, guidelines, and affiliatedpublications and organizations, see the IAS Home Page: http://www.athero.org

Executive Directors:

Administration, Education, and Scientific Affairs: Emanuela Folco, Ph.D., International Atherosclerosis Society, Via A. Appiani 7, 20121Milan (ITALY), Tel.: +39 02 29061879, Fax: + 39 02 29063581, E-mail: [email protected]

Fellowships, Finances, and Legal Affairs: Ann Stephens Jackson, M.B.A., International Atherosclerosis Society, 6535 Fannin, MS A-601,Houston, TX 77030 (USA), Tel: +1-713-797-9620, Fax: +1-713-797-9507, E-mail: [email protected]

International Atherosclerosis Society

Forthcoming Scientific Congresses of the IAS

2nd International Course Integrated Biomarkers – Translational Medicine Modelsin Cardiocerebrovascular and Inflammatory Diseases: Diagnosis, Prevention,Therapy and Drug DevelopmentLugano, Switzerland, Spring 2007Scientific Organzing Secretariat E-mail: [email protected]

XVI International Symposium Drugs Affecting Lipid MetabolismNew York, NY, USA, October 4–7, 2007Scientific Organizing Secretariat E-mail: [email protected] – [email protected]

XV International Symposium on AtherosclerosisBoston, MA, USA, June 14–18, 2009Scientific Organizing Secretariat E-mail: [email protected]

Zahi A. Fayad, PhD President

SAIP Membership Application

Name: _______________________________________________________________________________

Degrees: MD DO PhD Other: _________________________________________

Affiliations: ____________________________________________________________________________

Clinic/Practice: _________________________________________________________________________

University: ____________________________________________________________________________

Position(s): ___________________________________________________________________________

Mailing address: _______________________________________________________________________

_____________________________________________________________________________________

City: ___________________________ State: ____ Zip/Postal Code: _________ Country: _____________

Phone: ___________________________________ Fax: _______________________________________

Email: _______________________________________________________________________________

Imaging Modalities: EBCT Carotid Ultrasound Peripheral Ultrasound MRI Lipid Management MDCT Other: ________________________

Interest in: Clinical Research Database Education Practice Guidelines

Annual Membership Fees Physician/Scientist - $200

Other* - $100 (Student, Post-doc, Fellow, Government Employee, Technologist) *Please enclose a letter of eligibility from your institution

Membership fees may be paid by personal or institutional check in US dollars payable to SAIP

A Welcome from the President of the Society of Atherosclerosis Imaging and Prevention (SAIP)

I extend to you a warm welcome and hope that you will wish to join our Society.

A membership benefit for all dues paying members is a complimentary subscription to the Journal Atherosclerosis. If you were tosubscribe to this Journal as an individual, the publication would cost you $200 per year, which is the amount you pay if you are aphysician or scientist for membership dues in SAIP.

Please note that SAIP is pledged to represent your interests in several forums including the American Heart Association (AHA)Council on Radiology, in committees and writing groups of the American College of Cardiology (ACC), in support of studiesconducted by the ACC relative to the use of imaging modalities as well at other forums throughout the year. SAIP is an officialaffiliate of the International Atherosclerosis Society.

We stand ready to represent many of the interests that are important to you and your colleagues. Your support is needed and isgreatly appreciated.

Sincerely,

Mail application to:

SAIP26804 Ridge Road

Damascus, MD 20872

Active Involvement in Research: Clinical Basic

SOCIETY OF

ATHEROSCLEROSIS

IMAGING AND

PREVENTION

Acknowledgements

The Organizing Committee wishes to express its thanks and appreciation to the sponsors of ISA 2006:

Platinum Level

PFIZER Inc.

Gold Level

SANOFI AVENTISASTRAZENECA

ROCHEUNILEVER

MERCK SHARP & DOHME - SCHERING PLOUGHFOURNIER PHARMA, a member of the SOLVAY Group

BRISTOL-MYERS SQUIBBTAKEDA PHARMACEUTICALS NORTH AMERICA, Inc.

ABBOTTKOWA COMPANY Ltd.ALPRO FOUNDATIONMERCK KgaA Germany

Silver Level

SCHERING PLOUGH S.p.A.MERCK SHARP & DOHME ITALIA S.p.A.

SANKYO PHARMA Inc.RECORDATI

GLAXOSMITHKLINENOVARTIS PHARMA AGCHIESI FARMACEUTICI

TAKEDA ITALIA FARMACEUTICI S.p.A.MERCK PHARMA S.p.A.

SIGMA-TAUESPERION THERAPEUTICS, Division of Pfizer Global Research & Development

Bronze LevelINDENA S.p.A.

PRONOVA BIOCARESCHERING S.p.A.

NUTRITION FOUNDATION OF ITALY - NFIMONSANTO COMPANY

WYETH

and

PFIZER ITALIA S.r.l.CV THERAPEUTICS EUROPE Ltd.DOMPE’ FARMACEUTICI S.p.A.

INSTITUT DE RECHERCHES INTERNATIONALES SERVIERWYETH S.p.A. Italy

SPA – SOCIETÀ PRODOTTI ANTIBIOTICIBIOCENTRIC Inc.

NICOX RESEARCH INSTITUTE S.r.l.B. BRAUN MEDIZINTECHNOLOGIE GMBH



Abstracts of the

XIV International Symposium on Atherosclerosis

Rome, Italy

June 18–22, 2006

supplements€¦ · or otherwise, or from any use or operation of any methods, products,...

Documents